Benzinga | Oct 26, 2021 06:50AM EDT

SVB Leerink Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $798

SVB Leerink analyst Geoffrey Porges maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and raises the price target from $785 to $798.